Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequence analysis to compare MCF7 Tamoxifen resistant cells with and without DLL1

ABSTRACT: RNA sequence analysis to compare MCF7 Tamoxifen resistant cells with and without DLL1

PROVIDER: PRJNA602464 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10918851_1.fastq.gz	Fastqsanger.gz
	SRR10918851_2.fastq.gz	Fastqsanger.gz
	SRR10918852_1.fastq.gz	Fastqsanger.gz
	SRR10918852_2.fastq.gz	Fastqsanger.gz
	SRR10918853_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNA sequence analysis to compare MCF7 Tamoxifen resistant cells with and without DLL1

Project description:Several signatures including Tgb pathway, cytokines, Notch signaling is altered whe DLL1 is reduced

2023-01-20 | GSE143989 | GEO

Transcriptomic profiles of MCF7-derived tamoxifen resistant cell lines

Project description:We report mRNA profiles of human breast cancer cell lines, MCF7 parental, and MCF7-derived tamoxifen resistant cell lines MCF7-TR1 and MCF7-TR2.

2023-10-25 | GSE241654 | GEO

CHIP-SEQ of FOXA1 in parental MCF7 cells and tamoxifen resistant MCF7 cells

Project description:ChIP sequencing of FOXA1 in MCF7 cells and tamoxifen resistant MCF7 cells

2016-11-01 | GSE75201 | GEO

ATAC sequence analysis to compare MMTV-PyMT tumor cells with and without Dll1

Project description:Several genes like Nfkb, Npy and Dll1 showed altered enrichment peaks between Dll1+ and Dll1- population of tumor cells.

2020-11-20 | GSE133736 | GEO

RNA sequence analysis to compare MMTV-PyMT tumor cells with and without Dll1

Project description:Several cell cycle genes were altered between Dll1+ and Dll1- population of tumor cells

2020-11-20 | GSE129198 | GEO

Expression data from JQ1 (0.2 uM) treated tamoxifen-resistant MCF7 cells

Project description:Estrogen signaling pathway is critical for breast cancer development and has remained the major adjuvant therapeutic target for this disease. Tamoxifen has been used in clinic for many years to treat ER-positive breast cancer. However a great many (30%) suffer relapse due to drug resistance. In this study, the bromodomain inhibitor JQ1 was found to down-regulate ERalpha gene expression and have anti-tumor effect in cultured tamoxifen-resisant breast cancer cells. We used microarrays to detail the global programme of gene expression in tamoxifen-resistant MCF7 cells treated with the bromodomain inhibitor JQ1. Tamoxifen-resistant breast cancer MCF7 cells were treated with DMSO (vehicle) or JQ1 (0.2 uM) for 24 hours before total RNA was purified for microarray. Each sample was triplicated.

2014-03-01 | E-GEOD-49124 | biostudies-arrayexpress

Expression data from JQ1 (0.2 uM) treated tamoxifen-resistant MCF7 cells

2014-03-01 | GSE49124 | GEO

Transcriptomic profiles of MCF7-derived tamoxifen resistant cell lines

Project description:Transcriptomic profiles of MCF7-derived tamoxifen resistant cell lines

| PRJNA1009046 | ENA

ATAC sequence analysis to compare MMTV-PyMT tumor cells with and without Dll1

Project description:ATAC sequence analysis to compare MMTV-PyMT tumor cells with and without Dll1

| PRJNA552361 | ENA

RNA sequence analysis to compare MMTV-PyMT tumor cells with and without Dll1

Project description:RNA sequence analysis to compare MMTV-PyMT tumor cells with and without Dll1

| PRJNA530514 | ENA